Browse August's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.
Sanjay Kalra considers the course of action when blood glucose remains high in someone who cannot, or will not, modify a high-carbohydrate diet. Read more
Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers. Read more
Who is at the highest risk for developing type 2 diabetes in their youth? What are the consequences of being diagnosed so young, and what can clinicians do to help? Browse the hub to find out
How can people with diabetes be supported during Ramadan? We examine the evidence and provide practical advice from experts on fasting with type 1 or type 2 diabetes. Browse the hub
Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers.
The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.
The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.
A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.
The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.
The rate of heart failure hospitalization rises more than the rate of major adverse cardiovascular events as vascular risk increases in people with type 2 diabetes, report researchers.
Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.
The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.